Xanthone analogs for the treatment of infectious diseases

Details Xanthone analogs for the treatment of infectious diseases Xanthone analogs for the treatment of infectious diseases

1996-03-20

1999-11-02

Feisee, Lila

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 25, 514 27, 514 32, 514 42, 514 43, 514277, 514279, 514290, 514297, 514430, 514432, 514437, 514449, 514451, 514453, 514454, 514503, 514185, 549223, 549388, 549390, 549392, 549393, A61K 3170, A61K 31435

Patent

active

059770775

ABSTRACT:
Therapeutic compositions for the treatment of infectious diseases are disclosed. These compositions comprise xanthones and xanthone derivatives, such as 2,3,4,5,6-pentahydroxyxanthone. Also disclosed are methods for the treatment of infectious diseases using such compounds.

REFERENCES:
patent: 3346579 (1967-10-01), Sheehan et al.
patent: 3639612 (1972-02-01), De Long et al.
patent: 3714194 (1973-01-01), Ulrich
patent: 3755593 (1973-08-01), Adams et al.
patent: 3829578 (1974-08-01), Fleming et al.
patent: 3887574 (1975-06-01), Ellis et al.
patent: 3947594 (1976-03-01), Randall
patent: 3948920 (1976-04-01), Nabih
patent: 3953602 (1976-04-01), Shemano
patent: 3957986 (1976-05-01), Carr et al.
patent: 3985783 (1976-10-01), Johnson et al.
patent: 4015017 (1977-03-01), Gazave et al.
patent: 4284627 (1981-08-01), Raether et al.
patent: 4290954 (1981-09-01), Onogi et al.
patent: 4335046 (1982-06-01), Horner
patent: 4539412 (1985-09-01), Archer
patent: 4585876 (1986-04-01), Fischer et al.
patent: 4661607 (1987-04-01), Koga et al.
patent: 4816479 (1989-03-01), Koga et al.
patent: 4996230 (1991-02-01), Gapinski
patent: 5070085 (1991-12-01), Markham
patent: 5093372 (1992-03-01), Uedo et al.
patent: 5281620 (1994-01-01), Denny et al.
The Merck Index, Tenth Edition, p. 689 (entry 4656)(1983).
Bentue-Ferrer et al., "Comparative Evaluation of Scavenger Properties of Exifonem, Piracetam and Vinburnine," Laboratory of Clinical and Experimental Pharmacology, pp. 323-328 (1988).
Descombe et al., "Determination of Exifone in Human Plasma and Urine by High-Performance Liquid Chromatography with Electro-Chemical Detection," J. Chromatogr. 496:345-353 (1989).
Hafuri et al., "Mechanism of Inhibition of Reverse Transcriptase by Quinone Antibiotics--II. Dependence on Putative Quinone Pocket on the Enzyme Molecule," J. Antibiotics XLI:1471-1478 (1988).
Porsolt et al., "Antagonism by exifone*, a new cognitive enhancing agent, of the amnesias induced by four benzo-diazepines in mice," Psychopharmacology 95:291-297 (1988).
Vennerstrom and Eaton, "Oxidants, Oxidant Drugs, and Malaria," J. Med. Chem. 31:1269-1277 (1988).
Barbare and Raynal, "Hepatite aigue associee a la prise d'axifone (Adlone.RTM.)," Therapie 45:47-52 (1990).
Chichmanian et al., "Exifone: quatre case d'hepatite," Gastroenterol Clin. Biol. 13:428-429 (1989).
Denjean et al., "Nouveautes en Hepatotoxicite Medicamenteuse," Ann. Gastroenterol. Hepatol. 26:293-298 (1990).
Larrey et al., "Hepatites probablement dues a l'exifone (Adlone.RTM.)," Gastroenterol Clin. Biol. 13:397-400 (1989).
Ouzan et al., "Atteintes hepatiques aigues graves a l'exifone," Therapie 45:436-437 (1990).
Pateron et al., "Hepatite mortelle probablement due a l'exifone (Adlone.RTM.)," Gastroenterol. Clin. Biol. 14:294-295 (1990).
Ghosal et al., "Chemical Constituents of Gentianaceae XXIV: Anti-Mycobacterium tuberculosis Activity of Naturally Occurring Xanthones and Synthetic Analogs," J. Pharm. Sci. 67:721-722 (1978).
Hambloch and Frahm, "QSAR With the Tuberculostatic Activity of Polyhydroxy Xanthones and Their .sup.13 C-NMR Chemical Shifts," Eur. J. Med. Chem. 20:71-77 (1985).
Hostettmann et al., Strategy in the Search for New Biologically Active Plant Constituents, Proceedings of0 the Phytochemical Society of Europe, v. 37, Phytochemistry of Plants Used in Traditional Medicine, K. Hostettmann, A. Marston, M. Maillard, and M. Hamburger (eds). Oxford Science Publishers (1995).
Sultanbawa, "Tetrahedron Report No. 84--Xanthonoids of Tropical Plants," Tetrahedron 36:1465-1506 (1980).
Wang et al., "Swertifrancheside, an HIV-Reverse Transcriptase Inhibitor and the First Flavone-Xanthone Dimer, from Swertia franchetiana," J. Nat. Prod. 57:211-217 (1994).

Affiliated with

Also associated with

Rating

Xanthone analogs for the treatment of infectious diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Xanthone analogs for the treatment of infectious diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Xanthone analogs for the treatment of infectious diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2135545